A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients Being Treated for an Exacerbation of CF-associated Lung Disease
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Mercaptamine (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARE-CF-1; CARE-CF2
- Sponsors NovaBiotics
- 28 Mar 2018 Planned End Date changed from 28 Feb 2018 to 30 Apr 2018.
- 28 Mar 2018 Planned primary completion date changed from 28 Feb 2018 to 30 Apr 2018.
- 21 Dec 2017 Planned End Date changed from 1 Nov 2017 to 28 Feb 2018.